The global onychomycosis market size was exhibited at USD 3.49 billion in 2022 and is projected to hit around USD 5.46 billion by 2032, growing at a CAGR of 4.57% during the forecast period 2023 to 2032.
Key Pointers:
Onychomycosis Market Report Scope
Report Coverage |
Details |
Market Size in 2023 |
USD 3.65 Billion |
Market Size by 2032 |
USD 5.46 Billion |
Growth Rate from 2023 to 2032 |
CAGR of 4.57% |
Base year |
2022 |
Forecast period |
2023 to 2032 |
Segments covered |
Type, Treatment |
Regional scope |
North America; Europe; Asia Pacific; Central and South America; the Middle East and Africa |
Key companies profiled |
Bausch Health Companies Inc.; GSK plc; Abbott; Pfizer Inc.; Bayer AG; Teva Pharmaceutical Industries Ltd.; Cipla Inc.; Merck & Co., Inc.; Novartis AG; Sun Pharmaceutical Industries Ltd. |
The growth of the onychomycosis market is attributable to the increasing incidence of onychomycosis and chronic diseases aided by rising awareness about treatment. The infection leads to psychological and social limitations which can limit an individual's ability to work and socialize which makes it important to provide effective and efficient treatment for patients suffering from the infection further propelling the market growth.
Rising rate of onychomycosis is the key factor contributing to the overall growth of the market. The infection, often known as toenail fungus or fungal nail infection, affects over 14% of the total population in the U.S. However, most people are unaware of how harmful toenail fungus is, despite it is extremely contagious in nature and increasing the risk of developing with age.
International organizations such as the Global Nail Fungus Organization are working with public health officials and healthcare professionals worldwide to increase awareness and improve the prevention and treatment of nail fungus across the globe. This is anticipated to propel the demand for therapeutics. Government initiatives such as Think Fungus by the Centers for Disease Control and Prevention (CDC), emphasize the significance of detecting fungal diseases such as onychomycosis, early enough in the course of a patient's condition to ensure the administration of relevant therapy. This is inducing a surge in demand for onychomycosis therapeutics and is expected to drive market growth in the country.
Furthermore, the key players are focusing on collaborations and partnerships to develop novel onychomycosis therapies and to maintain their competitive position in the market. For instance, in August 2022, Moberg Pharma AB entered into a distribution agreement with Padagis Israel Agencies Ltd. that is expected to give Padagis exclusive rights for selling and marketing MOB-015, a treatment for onychomycosis in Israel. Moreover, innovations to address the concerns such as improving patient compliance and reducing the dosage are expected to fuel the market growth. For instance, in October 2021, Intas Pharmaceuticals launched SB 100mg under the brand name Itaspor-SB Forte/Subawin which is the world's first Super Bioavailable Itraconazole. This initiative is expected to significantly increase patient compliance and reduce the cost of therapy.
Some of the prominent players in the Onychomycosis Market include:
Segments Covered in the Report
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2032. For this study, Nova one advisor, Inc. has segmented the global Onychomycosis market.
By Type
By Treatment
By Region